Etanercept allergy and anaphylaxis.

作者: ANNE QUISMORIO , BHAUMIK BRAHMBHATT , MINDY HOUNG , RICHARD S. PANUSH

DOI: 10.3899/JRHEUM.120791

关键词: AllergyAnaphylaxisRheumatoid arthritisEtanerceptRashSulfasalazineDermatologyAnesthesiaHydroxychloroquinePrednisoneMedicine

摘要: To the Editor: Etanercept has been an effective, well tolerated medication with uncommon and usually acceptable adverse effects. We are aware of only 4 reports describing possible/probable etanercept allergy/anaphylaxis1,2,3,4,5. describe 2 patients allergic/anaphylactoid reactions to etanercept, review literature, comment on pertinent management issues. A 49-year-old woman a history atopy anaphylactoid/angioedematous symptoms soy milk developed rheumatoid arthritis (RA) in 2009. She was started prednisone, minocycline, sulfasalazine, ibuprofen, hydroxychloroquine, poor response. then prescribed 50 mg weekly subcutaneously, which rendered her asymptomatic. However, after several months she reported increasingly frequent severe episodes characterized by urticaria swelling periorbital regions tongue within hours following administration requiring diphenhydramine, epinephrine, corticosteroids. Etanercept discontinued there no recurrence these events. A 27-year-old presented 2005 persistent rash, fevers, … Address correspondence Dr. R.S. Panush, 2011 Zonal Ave., HMR 711, Keck School Medicine, University Southern California, Los Angeles, CA 90032, USA. E-mail: panush{at}usc.edu

参考文章(12)
Atayik E, Kaptanoglu E, Abadoglu O, Epozturk K, Successful rapid rituximab desensitization for hypersensitivity reactions to monoclonal antibodies in a patient with rheumatoid arthritis: a remarkable option. Journal of Investigational Allergology and Clinical Immunology. ,vol. 21, pp. 319- ,(2011)
Pieternella M. Houtman, Tim L. Jansen, Rob Blanken, Anaphylactic reaction in a patient with rheumatoid arthritis: a rare side effect of methotrexate with etanercept as a provoking factor? Jcr-journal of Clinical Rheumatology. ,vol. 12, pp. 321- 322 ,(2006) , 10.1097/01.RHU.0000250298.57783.B5
Sophie Martin Du Pan, Silvia Dehler, Adrian Ciurea, Hans-Rudolf Ziswiler, Cem Gabay, Axel Finckh, , Comparison of Drug Retention Rates and Causes of Drug Discontinuation Between Anti―Tumor Necrosis Factor Agents in Rheumatoid Arthritis Arthritis & Rheumatism. ,vol. 61, pp. 560- 568 ,(2009) , 10.1002/ART.24463
Ilaria Puxeddu, Lucia Giori, Valeria Rocchi, Laura Bazzichi, Stefano Bombardieri, Antonio Tavoni, Paola Migliorini, Isabella Del Corso, Hypersensitivity reactions during treatment with infliximab, etanercept, and adalimumab. Annals of Allergy Asthma & Immunology. ,vol. 108, pp. 123- 124 ,(2012) , 10.1016/J.ANAI.2011.11.004
Omer Faruk Sendur, Yasemin Turan, Isil Karatas Berkit, Engin Tastaban, Angio-oedema in a patient treated with etanercept for rheumatoid arthritis. Basic & Clinical Pharmacology & Toxicology. ,vol. 104, pp. 488- 490 ,(2009) , 10.1111/J.1742-7843.2009.00401.X
Paul J Anderson, None, Tumor necrosis factor inhibitors : Clinical implications of their different immunogenicity profiles Seminars in Arthritis and Rheumatism. ,vol. 34, pp. 19- 22 ,(2005) , 10.1016/J.SEMARTHRIT.2005.01.005
Paul Anderson, James Louie, Anna Lau, Michael Broder, None, Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors. Current Rheumatology Reports. ,vol. 7, pp. 3- 9 ,(2005) , 10.1007/S11926-005-0002-2
Roy Fleischmann, Scott W Baumgartner, Michael H Weisman, Thomas Liu, Barbara White, Paul Peloso, Long term safety of etanercept in elderly subjects with rheumatic diseases Annals of the Rheumatic Diseases. ,vol. 65, pp. 379- 384 ,(2006) , 10.1136/ARD.2005.035287
Ditina Desai, Raphaela Goldbach-Mansky, Joshua D Milner, Ronald L Rabin, Keith Hull, Frank Pucino, Nona Colburn, Anaphylactic Reaction to Anakinra in a Rheumatoid Arthritis Patient Intolerant to Multiple Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs Annals of Pharmacotherapy. ,vol. 43, pp. 967- 972 ,(2009) , 10.1345/APH.1L573
Todd A Kerensky, Alice B Gottlieb, Shimrat Yaniv, Shiu-chung Au, Etanercept: efficacy and safety for approved indications. Expert Opinion on Drug Safety. ,vol. 11, pp. 121- 139 ,(2012) , 10.1517/14740338.2012.633509